Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07220060 in advanced solid tumors (phase 1/2a)
jRCT2031230121Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jun 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of atirmociclib in breast cancer, non-small cell lung cancer (NSCLC), prostate cancer (PCa) and 4 more (4 arms), sponsored by Pfizer. Primary endpoints: Number of participants with dose-limiting toxicities (DLTs), Incidence of clinically significant adverse events, laboratory abnormalities, and vital sign abnormalities and 3 more. Started Jun 2023; status: active, not recruiting.
02
Drugs
atirmociclib
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)prostate cancer (PCa)castration-resistant prostate cancer (CRPC)colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031230121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230121.